Dear Colleagues,

SMaRT-IO; Immunotherapy in patients with **S**kin **M**alignancy **a**nd **R**enal **T**ransplant

We invite you to contribute to a multi-centre service evaluation of immunotherapy in renal transplant recipients with melanoma, cutaneous squamous cell carcinoma or Merkel cell carcinoma. Developed with dermatologists and renal physicians, the project is supported by the National Oncology Trainees Collaborative for Healthcare Research (NOTCH) initiative and the UK Skin Cancer Clinical Trials Group.

Immunotherapy is standard treatment for skin cancer and has improved patient outcomes. Renal transplant recipients face increased skin cancer risk from the long-term immunosuppression medications required to prevent organ rejection. Despite this, they are excluded from major trials because of concerns about serious side effects, including graft damage or rejection. Evidence is largely limited to small case series and reports, with minimal UK data and no national consensus on treatment.

We aim to address this gap by collecting data on all renal transplant recipients with localised, advanced or metastatic skin malignancy who started immunotherapy with adjuvant or palliative intent between 1st January 2016 and 31st December 2025. Anonymised data will be collected through a pre-approved survey on the secure REDCap platform, using a pre-defined protocol.

Please discuss participation with your Trust Audit department as early as possible. Given the small sample sizes expected at each centre, a data sharing agreement is required. Local project leads will receive the agreement and protocol.

To participate, please email Sophie Trotter (sophie.trotter4@nhs.net) for further information. Once we receive your completed data sharing agreement, we will share the collection tool so data collection can begin. We anticipate preparing the project for publication in late 2027.

Yours sincerely,

Dr Sophie Trotter

Medical Oncology Registrar,
Weston Park Cancer Centre,
Sheffield
NIHR Academic Clinical Fellow,
University of Sheffield

Dr Maria Hadjiyiangou

Medical Oncology Registrar,
Weston Park Cancer Centre,
Sheffield

Prof Sarah Danson

Consultant Medical Oncologist,
Weston Park Cancer Centre,
Sheffield
Professor of Medical Oncology,
University of Sheffield

On behalf of the SMART-IO study team.